metastatic melanoma

Bristol-Myers Squibb (BMS) has launched a dual immunotherapy treatment for metastatic melanoma, a type of advanced skin cancer. The therapy combines two immune checkpoint inhibitors to enhance anti-tumor responses.

Regeneron Pharmaceuticals faces investor claims of inflating stock prices by overstating the potential of a skin cancer treatment's clinical trial, which later failed to meet approval benchmarks. Investors allege the company minimized risks of trial delays while describing the drug combination as a 'potential blockbuster,' leading to significant stock price declines after the trial's failure was disclosed.